Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rapid Micro Biosystems (RPID) Cash & Equivalents (2020 - 2025)

Rapid Micro Biosystems' Cash & Equivalents history spans 6 years, with the latest figure at $100000.0 for Q4 2025.

  • On a quarterly basis, Cash & Equivalents fell 50.0% to $100000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $100000.0, a 50.0% decrease, with the full-year FY2025 number at $100000.0, down 50.0% from a year prior.
  • Cash & Equivalents hit $100000.0 in Q4 2025 for Rapid Micro Biosystems, down from $18.9 million in the prior quarter.
  • Over the last five years, Cash & Equivalents for RPID hit a ceiling of $219.6 million in Q3 2021 and a floor of $100000.0 in Q4 2023.
  • Historically, Cash & Equivalents has averaged $41.0 million across 5 years, with a median of $18.9 million in 2025.
  • Biggest five-year swings in Cash & Equivalents: crashed 99.91% in 2022 and later skyrocketed 18806.0% in 2025.
  • Tracing RPID's Cash & Equivalents over 5 years: stood at $178.4 million in 2021, then plummeted by 84.83% to $27.1 million in 2022, then crashed by 99.63% to $100000.0 in 2023, then skyrocketed by 100.0% to $200000.0 in 2024, then crashed by 50.0% to $100000.0 in 2025.
  • Business Quant data shows Cash & Equivalents for RPID at $100000.0 in Q4 2025, $18.9 million in Q3 2025, and $18.3 million in Q2 2025.